BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment
- License agreement includes
- Gloria Biosciences expected to begin bridging study to support potential approval and commercialization of motixafortide in the territory in stem cell mobilization -
- Gloria Biosciences expected to initiate randomized Phase 2/3 first-line pancreatic cancer clinical trial, evaluating motixafortide in combination with PD-1 inhibitor *zimberelimab and standard of care combination chemotherapy -
The license agreement provides for a
In addition, the transaction included an equity investment of
Under the terms of the license agreement, GloriaBio will be responsible for development and commercialization of motixafortide in
In addition, GloriaBio plans to initiate a Phase 2/3 first-line pancreatic cancer clinical trial evaluating motixafortide in combination with PD-1 inhibitor *zimberelimab and standard of care combination chemotherapy.
"We are tremendously pleased by the swift closing of this significant licensing agreement for the Asian market, which brings substantial benefits to
"We are very pleased to enter into this strategic partnership with
About Pancreatic Cancer in
At nearly 240,000 reported cases in 2022, it is estimated that
About Multiple Myeloma and Autologous Stem Cell Transplantation in
Multiple myeloma is an incurable blood cancer that affects some white blood cells called plasma cells, which are found in the bone marrow. When damaged, these plasma cells rapidly spread and replace normal cells in the bone marrow.
In 2022, it is estimated that
Autologous stem cell transplantation (ASCT) can be an important treatment paradigm for a number of blood cancers, including multiple myeloma. In
*About Zimberelimab (YuTuo®)
Zimberelimab is a fully human anti-PD-1 monoclonal antibody. GloriaBio is developing and commercializing zimberelimab in
About Gloria Biosciences
Gloria Biosciences is a commercial stage biopharma company focused on the development and commercialization of novel or highly differentiated immunotherapies and biologics for oncology. Toward the company's ultimate goal of improving accessibility, affordability, and availability for patients with innovation, Gloria Biosciences is striving to build a pipeline of more efficacious and patient-centered treatments to address unmet medical needs, driven by the company's efficient execution of clinical development, proven fast-to-market commercialization ability, world-class GMP-compliant manufacturing capability and global partnerships.
Forward Looking Statement
Various statements in this release concerning
View original content:https://www.prnewswire.com/news-releases/biolinerx-announces-closing-of-exclusive-license-agreement-to-motixafortide-in-asia-and-concurrent-strategic-equity-investment-301954789.html